Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $180 million, the company announced.

The voucher was awarded following the U.S. Food and Drug Administration's accelerated approval of KRESLADI (marnetegragene autotemcel). The biotechnology company plans to use the proceeds to support its cardiovascular gene therapy pipeline.

"The monetization of our PRV, following the FDA approval of KRESLADI, provides meaningful non-dilutive capital and extends our cash runway into the second quarter of 2028," said Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals.

A Rare Pediatric Disease Priority Review Voucher is granted by the FDA to sponsors of approved therapies for certain rare pediatric diseases. The voucher may be used to obtain priority review for a subsequent marketing application or sold to another sponsor. The program was reauthorized in February 2026.

Rocket's cardiovascular pipeline includes clinical-stage programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy. The company expects its cash runway to extend into the second quarter of 2028 following this transaction.

Rocket Pharmaceuticals is a biotechnology company that develops gene therapies for rare cardiovascular diseases, with additional programs in hematology and immunology. The company's cardiovascular pipeline targets three major inherited cardiomyopathy subtypes, representing more than 100,000 patients in the United States and European Union according to the company.